Sen. Chuck Grassley during a Judiciary Committee hearing last year. (Photo: Chip Somodevilla/Getty Images)

A key Senate panel seemed to hone in yesterday on some bipartisan ideas to cut federal spending on prescription drugs.

The big picture: Members of the Senate Finance Committee were mostly interested in proposals that would cut payments to insurance companies and doctors, though some also raised questions about pharmaceutical companies.

Details: Republicans and Democrats were both open to restructuring Medicare Part D, including payments to insurers.

  • “There’s reporting that patterns of overbidding exist that may indicate a potential gaming of the system," Finance Chairman Chuck Grassley told Axios, alluding to a recent Wall Street Journal story that said insurers have pocketed an extra $9.1 billion because of the way they estimate their costs.

In Medicare Part B, senators discussed changing the way the government reimburses doctors for the drugs they buy — "getting away from a percentage, which creates an incentive to go with the most expensive possible prescription and instead going with something closer to a flat fee," Sen. Pat Toomey said.

  • Doctors and hospitals have fought such changes before, and are fighting a similar proposal from the Trump administration. Critics say the current arrangement gives doctors an incentive to use the most expensive drugs, because they collect a percentage of the cost.

There was also support for changing the way pharmacy benefit managers handle their rebates, which the pharmaceutical industry may support and Trump is also considering.

"I thought there was a big swath of ground for bipartisanship," Sen. Ron Wyden said.

Grassley also hinted at more dramatic price cuts for drugs in an interview, but offered few details.

  • With more transparency throughout the system, "the companies have to justify their price increases and have uniform pricing," he said. "Whether I buy a drug or you buy a drug, there ought to be one price for a drug and everybody ought to pay the same thing."
  • A source familiar with Grassley's thinking said he was not advocating for price controls.
  • Other committee Republicans also questioned the gap between drug companies' profits and their research spending, but did not endorse any proposals to limit those profits.

Go deeper

Felix Salmon, author of Capital
1 hour ago - Economy & Business

Wall Street is living up to its bad reputation

Illustration: Sarah Grillo/Axios

Recent headlines will have you convinced that Wall Street is hell-bent on living up to all of its stereotypes.

Driving the news: Goldman Sachs is the biggest and the boldest, paying more than $5 billion in fines in the wake of the 1MDB scandal, in which billions were stolen from the people of Malaysia.

2 hours ago - Health

Ex-FDA chief: Pence campaigning after COVID exposure puts others at risk

Former FDA commissioner Scott Gottlieb said "the short answer is yes" when asked whether Vice President Mike Pence is putting others at risk by continuing to campaign after several aides tested positive for COVID-19, stressing that the White House needs to be "very explicit about the risks that they're taking."

Why it matters: The New York Times reports that at least five members of Pence's inner circle, including his chief of staff Marc Short and outside adviser Marty Obst, have tested positive for the virus. Pence tested negative on Sunday morning, according to the VP's office, and he'll continue to travel for the final stretch of the 2020 campaign.

Pence to continue traveling despite aides testing positive for COVID-19

Marc Short with Pence in March. Photo: Drew Angerer/Getty Images

Marc Short, Vice President Mike Pence’s chief of staff, tested positive for the coronavirus Saturday and is quarantining, according to a White House statement.

Why it matters: Short is Pence's closest aide, and was one of the most powerful forces on the White House coronavirus task force. Pence and second lady Karen Pence tested negative for the virus on Sunday morning, according to the vice president's office.